Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Share-based Compensation: 2015-2025

Historic Share-based Compensation for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to $2.2 million.

  • Editas Medicine's Share-based Compensation fell 53.60% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 47.71%. This contributed to the annual value of $21.4 million for FY2024, which is 8.18% up from last year.
  • Per Editas Medicine's latest filing, its Share-based Compensation stood at $2.2 million for Q3 2025, which was down 16.37% from $2.7 million recorded in Q2 2025.
  • Editas Medicine's Share-based Compensation's 5-year high stood at $13.5 million during Q2 2021, with a 5-year trough of $2.2 million in Q3 2025.
  • Its 3-year average for Share-based Compensation is $4.5 million, with a median of $4.7 million in 2023.
  • Per our database at Business Quant, Editas Medicine's Share-based Compensation skyrocketed by 149.70% in 2021 and then plummeted by 60.73% in 2025.
  • Over the past 5 years, Editas Medicine's Share-based Compensation (Quarterly) stood at $7.7 million in 2021, then dropped by 29.95% to $5.4 million in 2022, then fell by 0.35% to $5.3 million in 2023, then declined by 24.79% to $4.0 million in 2024, then tumbled by 53.60% to $2.2 million in 2025.
  • Its Share-based Compensation stands at $2.2 million for Q3 2025, versus $2.7 million for Q2 2025 and $3.0 million for Q1 2025.